# Phase 4 schizophrenia trials recruiting: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 4 for schizophrenia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 schizophrenia trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/schizophrenia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07927946 | Higher-Dose Maintenance With ERZOFRI 351 mg in Adults With Schizophrenia | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927946) |
| May 29, 2026 | NCT07615075 | Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With... | University of Maryland, Baltimore | Phase 4 | Not yet recruiting | Schizophrenia, Schizo Affective Disorder, Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615075) |
| October 28, 2025 | NCT07221877 | A Study to Evaluate the Effect of KarXT on Urological Safety | Bristol-Myers Squibb | Phase 4 | Recruiting | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221877) |
| September 4, 2025 | NCT07153835 | Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study | Sher-E-Bangla Medical College | Phase 4 | Not yet recruiting | Schizophrenia | 505 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07153835) |
| August 5, 2025 | NCT07105111 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While... | Neurocrine Biosciences | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105111) |
| July 20, 2025 | NCT07075237 | Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia | Jiangsu Province Nanjing Brain Hospital | Phase 4 | Not yet recruiting | Schizophrenia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07075237) |
| May 14, 2025 | NCT06969755 | Biomarkers to Enhance Early Schizophrenia Treatment | Northwell Health | Phase 4 | Recruiting | Schizophenia Disorder | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06969755) |
| April 11, 2025 | NCT06924255 | An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in... | Collaborative Neuroscience Research, LLC | Phase 4 | Not yet recruiting | Schizophrenia Disorders | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06924255) |
| April 11, 2025 | NCT06923891 | An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients | Vanguard Research Group | Phase 4 | Not yet recruiting | Schizophrenia | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06923891) |
| August 20, 2024 | NCT06562608 | Anticholinergic Deprescription in Schizophrenia | Sponsor not shown (see the record) | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06562608) |
| August 9, 2024 | NCT06546475 | A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine | National Taiwan University Hospital | Phase 4 | Not yet recruiting | Psychosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06546475) |
| December 18, 2023 | NCT06174116 | Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | University of Massachusetts, Worcester | Phase 4 | Recruiting | Schizophrenia, Schizo Affective Disorder | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06174116) |
| July 25, 2023 | NCT05958875 | The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a... | Sponsor not shown (see the record) | Phase 4 | Recruiting | Schizophrenia and Related Disorders, Early Treatment-Resistance | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05958875) |
| April 21, 2023 | NCT05823532 | Anti-Inflammatory Challenge in Schizophrenia | Emory University | Phase 4 | Recruiting | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05823532) |
| December 13, 2022 | NCT05648591 | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents | Vanda Pharmaceuticals | Phase 4 | Recruiting | Schizophrenia, Bipolar I Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05648591) |
| April 7, 2022 | NCT05316883 | Biomarkers in Clozapine-responding Schizophrenia | Sponsor not shown (see the record) | Phase 4 | Recruiting | Schizophrenia, Psychosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05316883) |
| January 26, 2022 | NCT05208190 | Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial | New York State Psychiatric Institute | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05208190) |
| October 8, 2020 | NCT04580134 | CLOZAPINE Response in Biotype-1 | University of Texas Southwestern Medical Center | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder | 524 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04580134) |
| July 21, 2020 | NCT04478838 | "Extended" (Alternate Day) Antipsychotic Dosing | Centre for Addiction and Mental Health | Phase 4 | Recruiting | Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04478838) |
| October 3, 2019 | NCT04113993 | Bazedoxifene -Treatment for Women With Schizophrenia | Sponsor not shown (see the record) | Phase 4 | Recruiting | Schizophrenia, Schizophreniform Disorders, Schizo Affective Disorder | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04113993) |
| July 2, 2018 | NCT03575000 | Bromocriptine for Patients With Schizophrenia and Prediabetes | VA Pittsburgh Healthcare System | Phase 4 | Not yet recruiting | Schizophrenia, PreDiabetes | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03575000) |
| April 11, 2018 | NCT03495024 | Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates | Corporal Michael J. Crescenz VA Medical Center | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03495024) |
| December 24, 2015 | NCT02639702 | Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia | Centre for Addiction and Mental Health | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02639702) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Centre for Addiction and Mental Health | 2 |
| Sher-E-Bangla Medical College | 1 |
| New York State Psychiatric Institute | 1 |
| University of Maryland, Baltimore | 1 |
| University of Texas Southwestern Medical Center | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Vanguard Research Group | 1 |
| National Taiwan University Hospital | 1 |
| Jiangsu Province Nanjing Brain Hospital | 1 |
| [Vanda Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/vanda-pharmaceuticals) | 1 |
| Corporal Michael J. Crescenz VA Medical Center | 1 |
| Emory University | 1 |
| Northwell Health | 1 |
| University of Massachusetts, Worcester | 1 |
| Collaborative Neuroscience Research, LLC | 1 |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 1 |
| VA Pittsburgh Healthcare System | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| Canada | 3 |
| Bangladesh | 1 |
| Denmark | 1 |
| Australia | 1 |
| China | 1 |
| Austria | 1 |
| Germany | 1 |
| Italy | 1 |
| Spain | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Warehouses in the United States](https://specstream.ai/data/businesses/warehouses/united-states)
- [Recycling centers in the United States](https://specstream.ai/data/businesses/recycling-centers/united-states)
- [Medical supply stores in the United States](https://specstream.ai/data/businesses/medical-supply-stores/united-states)
- [Geriatric medicine practices in the United States](https://specstream.ai/data/businesses/geriatric-medicine-practices/united-states)
